DIVIS LABORATORIES

BSE: 532488 19 Aug 2025

Healthcare

₹ 6082.8

Divi's Laboratories Ltd. specializes in Pharmaceuticals within the Healthcare sector.

DIVIS LABORATORIES

BSE: 532488 19 Aug 2025

Healthcare

₹ 6082.8

Divi's Laboratories Ltd. specializes in Pharmaceuticals within the Healthcare sector.

Book Value

564.0

Dividend Yield

0.49%

Debt to Equity

0.0

Stock P/E

70.0

Market Cap

1,61,343 Cr

DIVIS LABORATORIES - Share Price & Details

Market Cap

₹1,61,343

High /Low

7,078 / 4,663

Stock P/E

70.0

Book Value

₹564.0

Dividend Yield

0.49

ROCE

20.4

ROE

₹15.4

Face Value

2.0

PEG Ratio

-7.31

EVEBITDA

₹45.5

Debt

4.00

CMP / FCF

197.0

Debt to equity

₹0.0

NP Ann

2,191

High price all time

7,078

Piotroski score

₹7.0

Graham Number

1,050

No. Eq. Shares

26.6

Net CF

₹50.0

Net profit

2,306

Price to book value

10.8

Interest Coverage

₹610.0

Low price all time

45.0

Industry PE

33.5

Reserves

₹14,916

Free Cash Flow

₹215

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
Shyama Computronics and Servic	1.48	0.93	0.67	0.00	5.33	35.5
Triochem Products Ltd.,	3.25	-4.52	NA	-18.44	0
DIVIS LABORATORIES LTD.	24760.0	5570.0	23570.0	20.95	1,61,343	70.0
CIPLA LTD.	53172.4	13031.3	50461.7	16.12	125177	23.2
TORRENT PHARMACEUTICALS LTD.	26110.0	5510.0	26160.0	16.28	123321	61.1

Peer Comparison Chart

About DIVIS LABORATORIES

Divi's Laboratories Ltd., with Security Code 532488, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Latest News

Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

(11 Aug 2025)

NSEI:DIVISLAB 1 Year Share Price vs Fair Value Explore Divi's Laboratories's Fair Values from the Community and select...

Divi's Laboratories Q1 Results: Stock falls after profit, margins miss estimates

(07 Aug 2025)

Divi's Laboratories Ltd. reported a 14% year-on-year growth in revenue at ₹2,410 crore, compared to ₹2,118 crore in the year-ago quarter.

Quarterly Table

Standalone Consolidated

Metrics	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	1,908.2	1,730.0	1,868.0	1,808.0	2,259.0	2,063.0	2,302.0	2,297.0	2,536.0	2,357.0
Expenses	1,419.5	1,239.0	1,394.0	1,317.0	1,542.0	1,442.0	1,573.0	1,550.0	1,655.0	1,614.0
Operating Profit	488.7	491.0	474.0	491.0	717.0	621.0	729.0	747.0	881.0	743.0
OPM %	25.61%	28.38%	25.37%	27.16%	31.74%	30.1%	31.67%	32.52%	34.74%	31.52%
Other Income	66.2	80.0	85.0	94.0	79.0	79.0	105.0	82.0	87.0	119.0
Interest	0.2	0.0	1.0	0.0	2.0	0.0	1.0	0.0	0.0	3.0
Depreciation	86.6	93.0	94.0	95.0	94.0	97.0	98.0	99.0	107.0	112.0
Profit before tax	468.0	478.0	464.0	490.0	700.0	603.0	735.0	730.0	861.0	747.0
Tax %	-31.9%	-27.8%	-26.3%	-26.9%	-24.1%	28.7%	-29.5%	-18.6%	-22.5%	25.4%
Net Profit	318.8	345.0	342.0	358.0	531.0	430.0	518.0	594.0	667.0	557.0
EPS in Rs	12.01	12.99	12.89	13.5	19.99	16.18	19.51	22.39	0	20.95

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	1,707.7	1,950.8	1,778.0	1,909.0	1,855.0	2,303.0	2,118.0	2,338.0	2,319.0	2,585.0
Expenses	1,299.4	1,463.2	1,274.0	1,430.0	1,366.0	1,572.0	1,496.0	1,622.0	1,576.0	1,699.0
Operating Profit	408.3	487.6	504.0	479.0	489.0	731.0	622.0	716.0	743.0	886.0
OPM %	23.91%	24.99%	28.35%	25.09%	26.36%	31.74%	29.37%	30.62%	32.04%	34.27%
Other Income	114.3	66.2	81.0	86.0	95.0	79.0	79.0	106.0	82.0	86.0
Interest	0.1	0.2	0.0	1.0	0.0	2.0	0.0	1.0	0.0	1.0
Depreciation	86.8	87.0	93.0	95.0	95.0	95.0	97.0	99.0	99.0	107.0
Profit before tax	435.6	466.5	492.0	469.0	489.0	713.0	604.0	722.0	726.0	864.0
Tax %	-29.6%	-31.2%	-27.6%	-25.8%	-26.8%	-24.5%	-28.8%	29.4%	18.9%	-23.4%
Net Profit	306.8	321.0	356.0	348.0	358.0	538.0	430.0	510.0	589.0	662.0
EPS in Rs	11.56	12.09	13.41	13.11	13.5	20.25	16.2	19.2	22.2	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	12%
5 Years:	12%
3 Years:	1%
TTM:	20%

Compounded Profit Growth
10 Years:	10%
5 Years:	11%
3 Years:	-9%
TTM:	40%

Stock Price CAGR
10 Years:	22%
5 Years:	23%
3 Years:	21%
1 Year:	59%

Compounded Sales Growth
10 Years:	12%
5 Years:	12%
3 Years:	1%
TTM:	19%

Compounded Profit Growth
10 Years:	10%
5 Years:	10%
3 Years:	-10%
TTM:	37%

Stock Price CAGR
10 Years:	22%
5 Years:	23%
3 Years:	21%
1 Year:	59%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

DIVIS LABORATORIES

DIVIS LABORATORIES

DIVIS LABORATORIES - Share Price & Details

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About DIVIS LABORATORIES

Latest News

Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Divi's Lab, Mankind Pharma among 7 largecap stocks below their 200 DMAs

Divis Laboratories posts consolidated Q1 FY26 PAT of Rs. 545 Cr

Divis Laboratories Faces Continued Stock Decline Amid Broader Market Challenges

DIVISLAB Outlook for the Week (August 11, 2025 – August 15, 2025)

Divi's Laboratories Q1 Results: Stock falls after profit, margins miss estimates

Divi's Laboratories' June-quarter profit, margin miss estimates

Divi’s Lab donates ₹3.21 crore to boost AU’s infrastructure

Divis Labs bucks weak pharma shares trend; hits new high on strong Q1 hopes

Divis Laboratories Sees Significant Open Interest Surge Amid Active Market Participation

Divis Laboratories Sees Significant Open Interest Surge Amid Increased Trading Activity

DIVISLAB Outlook for the Week (June 30, 2025 – July 04, 2025)

DIVISLAB Outlook for the Week (June 09, 2025 – June 13, 2025)

Divi’s Lab shares up 3% after Q4 PAT surges 26% YoY. Should you invest?

Divis Labs Share Price Live Updates: Divis Labs Trading Insights

Divi's Laboratories inks manufacturing and supply agreement with global pharma company

Divi's Labs share up 4%, hits record high on inking supply deal; details

Divis Lab inks long-term global pharma deal

DIVIS LAB ENTERS INTO A LT MANUFACTURING AND SUPPLY AGREEMENT WITH A GLOBAL PHARMA CO

Divi's Laboratories share price rises 6% post Q4 results, dividend announcement: Time to buy or sell?

Stocks to buy in 2025: BHEL, Divi’s Laboratories among 5 stocks that could give 10-40% return

Stocks to buy for short term: From Divi's Labs, IRFC to Concor— experts suggest THESE 5 stock picks

Divi’s Labs Shares Jump Over 5%, Hits 52-Week High: Here's Why

From Vodafone Idea, BEL, Divi’s Lab to Premier Energies- Here are 8 stocks to watch

Divi’s Laboratories shares rally 6% on strong Q4 show; should you buy, sell or hold?

Divis and Delhivery gain up to 11%; Heres how market guru Anil Singhvi views companies earnings

Strong growth seen for Divi's Laboratories, but upside capped by valuations

Analyst predicts fresh upside for Divi’s Labs if ₹6,410 breaks | Tap to know more | Inshorts

Divi’s Labs Surges 6% On Q4 Beat; SEBI RA Thoviti Brahmachary Predicts Fresh Upside If ₹6,410 Breaks By Stocktwits

Divi's Labs shares gain 4% on strong Q4 show; eyes double-digit growth for FY26

Divis Laboratories Achieves 52-Week High, Signaling Strong Market Performance and Operational Efficiency

Divi’s Labs Q4 Results: Profit up 23% YoY, beats estimates; declares ₹30 dividend

Q4 Results Live: Data Patterns Profit Up, Margin Contracts; Zen Technologies Profit Jumps

Divi’s Laboratories Q4 results: PAT surges 26% YoY, revenue up 12%

Divis Labs Share Price Live Updates: Divis Labs Weekly Performance Highlights

Divis Laboratories Faces Short-Term Decline Amid Broader Market Volatility

Divi’s Labs inks long-term pact with global pharma firm to make, supply advanced intermediates

Stock Picks: Sagar Doshi suggests Divis Lab, HCL Tech, Marico shares to buy amid Indo-Pak conflict

Divi's Laboratories Insiders Sold ₹620m Of Shares Suggesting Hesitancy

Citi raises its price target on its top pharma pick, sees a 19% upside on the stock

Divis Labs jumps on signing long-term manufacturing pact with global pharma major

Stock to buy today: Divi’s Laboratories (₹6,215.55) – BUY

Divi's Laboratories Shows Strong Financial Growth and Market Positioning Amid Evaluation Adjustment

Divi’s Laboratories Shares Rally 5% Iking Deal with Global Pharma Company

Divi's Labs jumps 4% after signing supply agreement with global pharma firm

Divis Laboratories enters into long term manufacturing and supply agreement

Divis Laboratories Inks Supply Pact With Global Pharmaceutical Entity

Divi's Labs Q3 Results: Stock surges on earnings beat, part of a key unit begins commercial operations

Divi’s Laboratories Q3 Results: Profit Rises 64%, Beats Estimates

Sell Divi's Laboratories, target price Rs 4,500: ICICI Securities

Divis Labs shares surge 5% on Q3 beat; target prices, outlook & more

Divi’s Laboratories Q3 Results: Net profit rises 64.5% YoY to ₹589 crore, stock surges nearly 4%

Divi's Labs: Strong Q3, growth outlook positive, valuation debate continues

Divis Labs shares 0.3% as Nifty gains

Stock to buy today: Divi’s Laboratories (₹5,998) BUY

Divis Labs share price 1.75 per cent

Divis Laboratories Stock Declines 3.15% on January 15, Underperforming Sector by 3.35%

Divi's Laboratories' (NSE:DIVISLAB) investors will be pleased with their splendid 231% return over the last five years

Divis Labs shares 2.26% as Sensex rises

Divis Labs shares 0.42% as Nifty gains

Divi’s laboratories begins operations at Kakinada unit III

Divis Labs Starts Commercial Operations At Kakinada Greenfield Project

Divis Labs shares 0.1% as Sensex

Divis Labs shares 0.35% as Sensex rises

Divi's Laboratories Limited's (NSE:DIVISLAB) Shareholders Might Be Looking For Exit

Divis Labs stock price down 0.35 per cent as Sensex climbs

Divis Labs stock price up 0.8 per cent as Sensex climbs

F&O Strategy: Divi’s Lab: Bull Call Spread

Divis Labs shares rise 0.65% as Nifty gains

Share price of Divis Labs jumps as Sensex drops 886.42 points

Divis Labs share price 0.2 per cent